| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FFAR3 |
| Uniprot No | O14843 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 280-346aa |
| 氨基酸序列 | SSGFQADFHELLRRLCGLWGQWQQESSMELKEQKGGEEQRADRPAERKTSEHSQGCGTGGQVACAES |
| 预测分子量 | 39.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与FFAR3重组蛋白相关的3篇参考文献，按文献名称、作者和摘要内容简要概括：
1. **"Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice"**
- **作者**: Kimura, I. et al.
- **摘要**: 本研究通过重组表达FFAR3(GPR41)蛋白，揭示了短链脂肪酸(如丙酸)通过激活肠道上皮细胞中的FFAR3受体，调控炎症因子分泌及免疫反应的分子机制。
2. **"Free Fatty Acid Receptor 3 Activation Suppresses Neuroinflammation and Ameliorates Neurodegeneration in a Mouse Model of Alzheimer’s Disease"**
- **作者**: Noh, Y. et al.
- **摘要**: 利用重组FFAR3蛋白进行体外实验，发现其特异性激动剂(如丙酸酯)可抑制小胶质细胞的炎症反应，并通过动物模型证实FFAR3激活对神经退行性疾病的潜在治疗作用。
3. **"Structural basis for ligand recognition and activation of FFAR3"**
- **作者**: Zhang, X. et al.
- **摘要**: 通过重组表达人源FFAR3蛋白并结合冷冻电镜技术，解析了FFAR3与短链脂肪酸结合的分子结构，揭示了其信号传导的构象变化机制。
(注：以上文献信息为示例，实际引用时建议通过PubMed或Sci-Hub等平台核对原文细节。)
**Background on FFAR3 Recombinant Protein**
Free Fatty Acid Receptor 3 (FFAR3), also known as GPR41. is a G protein-coupled receptor (GPCR) that binds short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These SCFAs are primarily produced by gut microbiota through the fermentation of dietary fiber, linking FFAR3 to critical roles in energy metabolism, immune regulation, and gut-brain communication. FFAR3 is expressed in various tissues, including the intestines, adipose tissue, and peripheral nervous system, where it modulates processes like hormone secretion, inflammation, and appetite control.
Recombinant FFAR3 protein is engineered in vitro using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, ligand interactions, and signaling mechanisms. Purified recombinant FFAR3 retains functional activity, enabling researchers to investigate its coupling with downstream effectors, such as Gi/o proteins, which inhibit cAMP production, or β-arrestin pathways.
Interest in FFAR3 stems from its therapeutic potential in metabolic disorders (e.g., obesity, diabetes), gastrointestinal diseases, and neurological conditions. Structural studies using recombinant FFAR3 have advanced understanding of SCFA binding pockets and receptor activation, guiding drug design for selective agonists/antagonists. Additionally, it serves as a tool to explore gut microbiome-host interactions, emphasizing its role as a mediator between microbial metabolites and human physiology.
In summary, FFAR3 recombinant protein is pivotal for deciphering SCFA signaling and developing targeted therapies for diseases influenced by diet, microbiota, and metabolic dysregulation.
×
